Deprescribing Science and Medication Optimization in Aging

Abstract

Polypharmacy and inappropriate medication use are prevalent challenges in the care of older adults, leading to increased risks of adverse drug events, falls, cognitive impairment, and hospitalizations. Deprescribing the planned and supervised process of dose reduction or stopping medications that may no longer be beneficial or may be causing harm has emerged as a critical component of medication optimization in the aging population. This review synthesizes current evidence, explores the mechanisms underlying age-related pharmacologic changes, and discusses practical strategies for implementing deprescribing in clinical practice. Emphasis is placed on the clinical relevance, recent advances, guideline recommendations, and the balance between risk minimization and therapeutic benefit in elderly patients.

Introduction

The global demographic shift toward an aging population has profound implications for health care systems, particularly regarding the management of multimorbidity and polypharmacy. Older adults frequently require multiple medications to manage chronic diseases, yet they are simultaneously at increased risk of adverse drug reactions (ADRs) due to altered pharmacokinetics, pharmacodynamics, and comorbidities. Deprescribing science has evolved as an evidence-based approach to safely reduce medication burden, enhance quality of life, and improve health outcomes for geriatric patients. Understanding the principles of deprescribing and medication optimization is essential for clinicians who care for aging populations.

Epidemiology / Disease Burden

Polypharmacy, commonly defined as the use of five or more medications, affects over 40% of adults aged 65 years and older in developed countries. Epidemiological data demonstrate a direct correlation between the number of prescribed medications and the risk of adverse drug events, hospitalizations, and mortality. Inappropriate prescribing, including the use of potentially inappropriate medications (PIMs) as identified by tools such as the Beers Criteria and STOPP/START criteria, is widespread. The economic burden includes increased health care utilization and costs associated with medication-related morbidity and mortality. Globally, interventions targeting medication optimization can reduce health care expenditures and improve patient-centered outcomes.

Pathophysiology

Aging is associated with significant physiological changes that impact drug absorption, distribution, metabolism, and excretion. Decreased renal and hepatic function, altered body composition, and changes in receptor sensitivity contribute to heightened drug sensitivity and vulnerability to side effects. Polypharmacy compounds these risks by increasing the potential for drug-drug and drug-disease interactions. The pathophysiology of adverse drug reactions in elderly patients is multifactorial, often involving cumulative pharmacodynamic effects and impaired homeostatic reserve. These factors necessitate a nuanced approach to medication management, prioritizing safety and individualized care.

Risk Factors

Major risk factors for polypharmacy and inappropriate medication use in older adults include advanced age, multimorbidity, cognitive impairment, fragmented care, and transitions between healthcare settings. Clinical inertia, lack of coordinated medication review, and insufficient patient-provider communication further exacerbate the risk. Social determinants, such as limited health literacy and inadequate support systems, can also impede optimal medication management. Recognition of these risk factors is essential for targeted interventions and proactive deprescribing.

Clinical Features

The clinical manifestations of polypharmacy and medication-related harm in the elderly are often nonspecific, including falls, delirium, functional decline, and worsening of baseline diseases. Adverse drug reactions may present atypically, complicating diagnosis and management. Frailty, reduced mobility, and cognitive changes can be both a consequence and a contributor to medication burden, creating a cycle of declining health status. Comprehensive medication review and vigilant clinical monitoring are essential to identify and address such features.

Diagnosis

Diagnosis of medication-related problems begins with a thorough medication reconciliation, including prescription drugs, over-the-counter products, and supplements. Tools such as the Beers Criteria, STOPP/START, and Medication Appropriateness Index facilitate the identification of PIMs and guide clinical decision-making. Structured assessment of renal and hepatic function, drug levels, and evaluation for drug-drug interactions are critical components. Collaboration with pharmacists, geriatricians, and interdisciplinary teams enhances diagnostic accuracy and supports safe deprescribing practices.

Treatment & Management

Deprescribing is a patient-centered, systematic process that involves identifying medications for discontinuation, prioritizing based on risk-benefit analysis, and implementing gradual dose reduction when indicated. Shared decision-making and patient education are fundamental to success. Tapering protocols and close monitoring for withdrawal or disease recurrence are necessary for certain drug classes such as benzodiazepines, antipsychotics, and antihypertensives. Comprehensive care plans should address non-pharmacologic alternatives, comorbidity management, and ongoing medication review. Interprofessional collaboration, including input from clinical pharmacists, enhances safety and efficacy.

Recent Advances / Emerging Therapies

Recent research highlights the efficacy of structured deprescribing interventions, including clinical decision support tools, pharmacist-led medication reviews, and patient-specific algorithms. Novel digital health solutions, such as electronic health record (EHR)-integrated deprescribing triggers, enable real-time identification of deprescribing opportunities. Randomized controlled trials have demonstrated reductions in PIMs, falls, and hospitalizations with targeted interventions. Emerging therapies focus on personalized medicine, leveraging pharmacogenomics and biomarker-driven approaches to optimize medication selection and minimize harm.

Guideline Recommendations

Leading organizations, including the American Geriatrics Society, European Geriatric Medicine Society, and NICE, recommend routine medication review and deprescribing as standard of care for older adults. Guidelines emphasize individualized assessment, risk stratification, and shared decision-making. Tools such as the Beers Criteria, STOPP/START, and deprescribing.org protocols are endorsed for clinical use. Integration of deprescribing into routine care, especially during care transitions and in patients with limited life expectancy, is strongly advocated.

Conclusion

Deprescribing science and medication optimization are integral to the care of aging populations, offering significant benefits in reducing adverse outcomes and enhancing quality of life. An evidence-based, structured approach grounded in clinical guidelines and tailored to individual patient needs can safely minimize medication burden. Ongoing education, interdisciplinary collaboration, and adoption of emerging technologies will further advance the field, supporting healthcare professionals in delivering optimal care to older adults.